J Physiol Wellcome Trust-funded researchers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Physiol Volume 533, Number 3, 881-889, June 15, 2001
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tarnopolsky, M. A.
Right arrow Articles by Rush, J. W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tarnopolsky, M. A.
Right arrow Articles by Rush, J. W. E.
Journal of Physiology (2001), 533.3, pp. 881-889
© Copyright 2001 The Physiological Society

Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans


Mark A. Tarnopolsky *†, Gianni Parise †, Martin J. Gibala †, Terry E. Graham ‡ and James W. E. Rush §


Departments of * Medicine (Neurology and Rehabilitation) and † Kinesiology, McMaster University, Hamilton, ‡ Department of Human Biology and Nutrition, University of Guelph, Guelph and § Department of Kinesiology, University of Waterloo , Waterloo, Ontario, Canada

  1. Myoadenylate deaminase (AMPD) deficiency is present in 1-2 % of the population. In theory, this deficiency may alter exercise energy metabolism by impairing the purine nucleotide cycle (PNC) and reducing tricarboxylic acid (TCA) cycle anaplerosis. The role of the PNC in TCA cycle anaplerosis is still a debated issue in physiology. Using patients with the AMPD1 mutation will allow a human 'knockout' approach to answering this question.
  2. Muscle AMPD activity and genotype (whole blood AMPD1 analysis) was used to classify participants into three groups: n = 3 with absence of AMPD activity and -/- AMPD1 genotype (homozygous); n = 4 with less than 50 % normal AMPD activity and +/- genotype (heterozygous) and n = 12 with normal AMPD activity and +/+ genotype (control). Biopsies were taken from the vastus lateralis muscle before and after incremental cycle ergometry exercise to exhaustion. The muscle biopsies were analysed for AMPD activity, purine nucleotides/nucleosides and bases, creatine, phosphocreatine, amino acids, and the TCA cycle intermediates malate, citrate and fumarate.
  3. Time to exhaustion on the cycle ergometer was not different between groups. Muscle adenosine monophosphate increased significantly with exercise for homozygous subjects as compared with the other groups (P < 0.05). Inosine monophosphate increased significantly after exercise for control (P < 0.05) but not for the homozygous subjects. There were no other between-group differences for any other measured variables.
  4. In summary, complete and partial muscle AMPD deficiency did not affect TCA cycle anaplerosis, phosphocreatine hydrolysis, energy charge or exercise performance.



This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
H. Fischer, M. Esbjornsson, R. L. Sabina, A. Stromberg, M. Peyrard-Janvid, and B. Norman
AMP deaminase deficiency is associated with lower sprint cycling performance in healthy subjects
J Appl Physiol, July 1, 2007; 103(1): 315 - 322.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Sports. Med.Home page
A Lucia, M A Martin, J Esteve-Lanao, A F San Juan, J C Rubio, J Olivan, and J Arenas
C34T mutation of the AMPD1 gene in an elite white runner.
Br. J. Sports Med., March 1, 2006; 40(3): e7 - e7.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
J. C. Rubio, M. A. Martin, M. Rabadan, F. Gomez-Gallego, A. F. San Juan, J. M. Alonso, J. L. Chicharro, M. Perez, J. Arenas, and A. Lucia
Frequency of the C34T mutation of the AMPD1 gene in world-class endurance athletes: does this mutation impair performance?
J Appl Physiol, June 1, 2005; 98(6): 2108 - 2112.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. K Kalsi, A. H.Y Yuen, I. M Rybakowska, P. H Johnson, E. Slominska, E. J Birks, K. Kaletha, M. H Yacoub, and R. T Smolenski
Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation--A potential mechanism of protection in heart failure
Cardiovasc Res, September 1, 2003; 59(3): 678 - 684.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
J. Rico-Sanz, T. Rankinen, D. R. Joanisse, A. S. Leon, J. S. Skinner, J. H. Wilmore, D. C. Rao, and C. Bouchard
Associations between cardiorespiratory responses to exercise and the C34T AMPD1 gene polymorphism in the HERITAGE Family study
Physiol Genomics, July 7, 2003; 14(2): 161 - 166.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Borza, C. V. Iancu, E. Pike, R. B. Honzatko, and H. J. Fromm
Variations in the Response of Mouse Isozymes of Adenylosuccinate Synthetase to Inhibitors of Physiological Relevance
J. Biol. Chem., February 21, 2003; 278(9): 6673 - 6679.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 The Physiological Society.